Zosano Pharma Announces Proposed Public Offering of Common Stock
09 4월 2019 - 5:01AM
Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage
biopharmaceutical company, today announced that it has commenced an
underwritten public offering of shares of its common stock. All of
the shares to be sold in the offering will be offered by Zosano. In
addition, Zosano intends to grant to the underwriter a 30-day
option to purchase up to an additional 15% of the shares of its
common stock offered in the public offering, on the same terms and
conditions. The offering is subject to market and other conditions,
and there can be no assurance as to whether or when the offering
may be completed, or the actual size or terms of the offering.
Zosano intends to use the net proceeds from the offering to fund
its ongoing development and preparation for potential
commercialization of Qtrypta™ (M207), and for working capital and
general corporate purposes.
Cantor Fitzgerald & Co. is the sole book-running manager for
the proposed offering.
A registration statement relating to these securities has been
filed with the U.S. Securities and Exchange Commission (SEC) and
became effective on March 27, 2019. The offering is being made only
by means of a written prospectus and prospectus supplement that
will form a part of the registration statement. A preliminary
prospectus supplement and the accompanying prospectus relating to
the offering will be filed with the SEC and will be available on
the SEC’s website at www.sec.gov. Alternatively, copies of the
preliminary prospectus supplement and the accompanying prospectus,
when available, may be obtained from Cantor Fitzgerald & Co.,
Attn: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY
10022, or by email at prospectus@cantor.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful, prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Zosano Pharma
Zosano Pharma Corporation is a clinical stage biopharmaceutical
company focused on providing administration of therapeutics to
patients using its intracutaneous delivery system, which consists
of titanium microneedles coated with drug that can enable rapid
systemic administration to patients. The company’s lead product
candidate is Qtrypta™ (M207), which is Zosano’s proprietary
formulation of zolmitriptan delivered via its intracutaneous
delivery technology for the treatment of migraine disease. In
February 2017, the company announced statistically significant
results from the ZOTRIP pivotal study and in February 2019, Zosano
announced the completion of the final milestone in its long-term
safety study.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Zosano, they are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor of the
Private Securities Litigation Reform Act of 1995, including
Zosano’s expected use of the proceeds of the proposed public
offering. Such forward-looking statements involve substantial risks
and uncertainties that could cause Zosano’s future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks
and uncertainties include, among others, the uncertainties related
to market conditions and the completion of the public offering on
the anticipated terms or at all. Zosano undertakes no obligation to
update or revise any forward-looking statements. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to Zosano’s business in
general, please refer to Zosano’s prospectus supplement to be filed
with the SEC, including the documents incorporated by reference
therein, which include Zosano’s Annual Report on Form 10-K filed
with the SEC on March 25, 2019, and Zosano’s other periodic reports
filed with the SEC.
Zosano Contact:Greg KitchenerChief Financial
Officer(510) 745-1200
PR Contact:Sylvia Wheeler and Alexandra
Santosswheeler@wheelhouselsa.com/asantos@wheelhouselsa.com
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024